Abbott India share price
NSE: ABBOTINDIABSE: 500488Pharmaceuticals & BiotechnologyMid Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹25,360.00.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹53,187 Cr183rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 12 Aug 2026
- 32.9
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 11 May 2026
- 11.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.62%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 12 Aug 2026
- 35.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Aug 2026
- 39.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 11 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 7,88155.2% delivered
Results
Standalone; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 12 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹1,814 Crup 6.09%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹429 Crup 8.51%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 23.6%
Revenue by year
Net profit by year, a loss in red
The years either side of a change of basis do not compare. From the year to Mar 2018, GST replaced excise duty on 1 Jul 2017, and revenue before that day includes the duty.
| ₹ crore | Sep 2024Filed 7 Nov | Dec 2024Filed 5 Feb | Mar 2025Filed 10 Jun | Jun 2025Filed 12 Aug | Sep 2025Filed 6 Nov | Dec 2025Filed 12 Feb | Mar 2026Filed 11 May | Jun 2026Filed 12 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,633 | 1,614 | 1,605 | 1,738 | 1,757 | 1,724 | 1,710 | 1,814 |
| Net profit | 359 | 361 | 367 | 366 | 415 | 376 | 395 | 429 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 22.0% | 22.3% | 22.9% | 21.0% | 23.6% | 21.8% | 23.1% | 23.6% |
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceutical, which carries all its revenue.
Valuation
Today, against the company's own history. Its history crosses a change of basis in the accounts in the year to Mar 2018: days before it are of the company before the change.PE ratio and valuation history
At or below today's level on 3% of 2,480 trading days over the last 10 years.
At or below today's level on 11% of 1,969 trading days since Nov 2018.
At or below today's level on 5% of 1,969 trading days since Nov 2018.
At or below today's level on 100% of 2,431 trading days over the last 10 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −13.1% | +9.7% | −23.1% | 2.5% |
| 3 years | +7.4% | +17.8% | −10.4% | 1.9% |
| 5 years | +13.3% | +17.6% | −5.1% | 1.7% |
Mutual funds holding it
164 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 58 of the 82 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 1 more fund filed its first portfolio on record, holding it.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 1
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 4
- AddedAdded. Funds that held more shares than at the end of the month before.
- 46
- CutCut. Funds that held fewer shares than at the end of the month before.
- 36
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 76
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 5
| Fund | |||
|---|---|---|---|
 SBI Large & Midcap FundSBI Mutual Fund | 3,08,000 | 2.06% | ₹835.5 Cr |
 Nippon India Multi Cap FundNippon India Mutual Fund | 1,47,614 | 0.74% | ₹400.4 Cr |
 Axis Midcap FundAxis Mutual Fund | 1,36,564 | 1.10% | ₹370.4 Cr |
 Canara Robeco Large and Mid Cap FundCanara Robeco Mutual Fund | 1,32,375 | 1.46% | ₹359.1 Cr |
| Nippon India Pharma FundNippon India Mutual Fund | 78,546 | 2.32% | ₹213.1 Cr |
 ICICI Prudential Healthcare FundICICI Prudential Mutual Fund | 64,361 | 2.54% | ₹174.6 Cr |
 Tata Mid Cap FundTata Mutual Fund | 50,000 | 2.31% | ₹135.6 Cr |
| Tata Large & Mid Cap FundTata Mutual Fund | 40,346 | 1.51% | ₹109.4 Cr |
| Tata India Pharma & Healthcare FundTata Mutual Fund | 33,086 | 5.94% | ₹89.7 Cr |
 PGIM India Midcap FundPGIM India Mutual Fund | 32,971 | 0.85% | ₹89.4 Cr |
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Abbott India in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Aurobindo PharmaAUROPHARMA | 90,432 | 24.4 | 2.4 | 12.5 | +9.1% | +9.5% | 10.5% | 11.5% | 0.00% |
 LupinLUPIN | 88,207 | 16.0 | 3.9 | 9.3 | +28.2% | +49.5% | 27.9% | 28.2% | 0.93% |
 Glenmark PharmaceuticalsGLENMARK | 61,147 | 34.0 | 5.8 | 12.5 | +32.9% | +138.4% | 18.6% | 39.8% | 0.12% |
 Alkem LaboratoriesALKEM | 59,149 | 27.4 | 4.3 | 19.5 | +13.4% | −5.6% | 16.7% | 16.5% | 1.07% |
 BioconBIOCON | 52,721 | 106.4 | 1.5 | 18.2 | +9.8% | +28.6% | 1.8% | 2.9% | 0.15% |
 IPCA LaboratoriesIPCALAB | 49,556 | 37.8 | 6.1 | 22.3 | +10.6% | +68.2% | 17.4% | 17.6% | 0.31% |
 Gland PharmaGLAND | 46,645 | 41.3 | 4.5 | 24.9 | +17.6% | +46.5% | 11.6% | 12.4% | 0.71% |
 Ajanta PharmaAJANTPHARM | 41,035 | 36.2 | 9.1 | 28.0 | +20.2% | +22.0% | 27.3% | 27.2% | 1.83% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 24 Jul 2026 | Final | ₹525.00 |
| 24 Jul 2026 | Special | ₹131.00 |
| 25 Jul 2025 | Final | ₹475.00 |
| 19 Jul 2024 | Final | ₹410.00 |
| 21 Jul 2023 | Final | ₹180.00 |
| 21 Jul 2023 | Special | ₹145.00 |
Latest announcements
Routine notices left out.Share news and announcements
Sep 2026
Aug 2026
12 Aug · Results
4 Aug · Board meeting
Meeting on 12 Aug 2026: quarterly results
Abbott India share price by year
Each calendar year to 2025.Abbott India share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 29,025.00 | −2.4% | 35,670.00 | 25,501.85 |
| 2024 | 29,741.00 | +30.2% | 30,195.85 | 22,761.10 |
| 2023 | 22,851.25 | +6.9% | 24,555.80 | 20,029.15 |
| 2022 | 21,367.20 | +9.7% | 21,842.45 | 15,562.60 |
| 2021 | 19,485.65 | +23.6% | 23,184.50 | 14,093.85 |
| 2020 | 15,769.10 | +20.6% | 18,301.70 | 12,319.30 |
| 2019 | 13,075.50 | +74.0% | 13,381.80 | 7,191.05 |
| 2018 | 7,516.65 | +36.0% | 8,593.35 | 5,250.75 |
| 2017 | 5,524.95 | +17.0% | 5,643.20 | 4,022.50 |
| 2016 | 4,722.30 | −21.4% | 5,930.90 | 4,392.85 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 25,485.00 | 25,485.00 | 24,650.00 | 25,030.00 | 24,924.44 | 7,881 | 55.2% |
| 22 Oct 2026 | 25,795.00 | 25,795.00 | 25,275.00 | 25,360.00 | 25,410.73 | 2,397 | 46.3% |
| 21 Oct 2026 | 25,910.00 | 26,055.00 | 25,135.00 | 25,680.00 | 25,746.81 | 3,422 | 62.2% |
| 19 Oct 2026 | 26,040.00 | 26,145.00 | 25,805.00 | 25,905.00 | 25,968.03 | 2,009 | 49.5% |
| 16 Oct 2026 | 26,070.00 | 26,230.00 | 25,910.00 | 26,170.00 | 26,097.90 | 3,831 | 64.2% |
| 15 Oct 2026 | 26,290.00 | 26,290.00 | 26,000.00 | 26,070.00 | 26,126.75 | 3,195 | 47.5% |
| 14 Oct 2026 | 25,800.00 | 26,550.00 | 25,750.00 | 26,295.00 | 26,129.29 | 6,143 | 50.8% |
| 13 Oct 2026 | 25,850.00 | 25,915.00 | 25,505.00 | 25,695.00 | 25,653.55 | 2,779 | 62.5% |
| 12 Oct 2026 | 26,000.00 | 26,100.00 | 25,500.00 | 25,790.00 | 25,846.87 | 2,659 | 52.1% |
| 9 Oct 2026 | 25,580.00 | 26,040.00 | 25,580.00 | 26,000.00 | 25,893.31 | 3,422 | 53.3% |
About Abbott India
Abbott India Limited sells branded medicines in India. It serves patients and the healthcare professionals who treat them. The company works in six therapy areas: gastrointestinal, women's health, metabolics, central nervous system, vaccines and multi-specialty. Its brands include Thyronorm, Digene, Cremaffin, Duphalac, Vertin, Udiliv and Influvac.
In gastrointestinal care, Udiliv is a hepatoprotective, a medicine that protects the liver, and is ranked the number one brand in that group in India on IQVIA data for the 12 months to March 2026. Thyronorm is its brand for thyroid care, and Digene is an antacid, a medicine for acidity. In women's health, its brands include Duphaston and Femoston. During the year to March 2026 the company ran about 13,000 continuing medical education programmes, which engaged nearly 2,50,000 healthcare professionals. In the same year it added semaglutide, a treatment for type 2 diabetes, through a collaboration with Novo Nordisk India, under the brand Extensior.
The company has a manufacturing plant in Goa that makes tablets and liquids, and its corporate headquarters in Mumbai. It follows a predominantly local sourcing model and works with local manufacturers on production. Its sales reach covers the whole country.
It was incorporated in 1944. Around 2001 the company was integrating the Knoll Pharmaceuticals business into a single platform. Today it draws on the wider Abbott healthcare business, which spans pharmaceuticals, diagnostics, nutrition and diabetes care.
- Legal name
- Abbott India Limited
- NSE symbol
- ABBOTINDIA
- BSE code
- 500488
- ISIN
- INE358A01014
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Feb 1966
- Face value
- ₹10
- CIN
- L24239MH1944PLC007330
- Corporate identity number, the registrar of companies' code for it